Dermatofibroma pathophysiology: Difference between revisions
Homa Najafi (talk | contribs) No edit summary |
Homa Najafi (talk | contribs) No edit summary |
||
Line 33: | Line 33: | ||
{{#ev:youtube|tq4xFLIw1TA}} | {{#ev:youtube|tq4xFLIw1TA}} | ||
== | ==Overview== | ||
The exact pathogenesis of [disease name] is not fully understood. | |||
OR | |||
It is thought that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3]. | |||
OR | |||
[Pathogen name] is usually transmitted via the [transmission route] route to the human host. | |||
OR | |||
Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell. | |||
OR | |||
[Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells]. | |||
OR | |||
The progression to [disease name] usually involves the [molecular pathway]. | |||
OR | |||
The pathophysiology of [disease/malignancy] depends on the histological subtype. | |||
==Pathophysiology== | |||
===Physiology=== | |||
The normal physiology of [name of process] can be understood as follows: | |||
===Pathogenesis=== | |||
*The exact pathogenesis of [disease name] is not completely understood. | |||
OR | |||
*It is understood that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3]. | |||
*[Pathogen name] is usually transmitted via the [transmission route] route to the human host. | |||
*Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell. | |||
*[Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells]. | |||
*The progression to [disease name] usually involves the [molecular pathway]. | |||
*The pathophysiology of [disease/malignancy] depends on the histological subtype. | |||
==Genetics== | |||
[Disease name] is transmitted in [mode of genetic transmission] pattern. | |||
OR | |||
Genes involved in the pathogenesis of [disease name] include: | |||
*[Gene1] | |||
*[Gene2] | |||
*[Gene3] | |||
OR | |||
The development of [disease name] is the result of multiple genetic mutations such as: | |||
*[Mutation 1] | |||
*[Mutation 2] | |||
*[Mutation 3] | |||
==Associated Conditions== | |||
Conditions associated with [disease name] include: | |||
*[Condition 1] | |||
*[Condition 2] | |||
*[Condition 3] | |||
==Gross Pathology== | |||
On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name]. | |||
==Microscopic Pathology== | |||
On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name]. | |||
{{Reflist|2}} | {{Reflist|2}} |
Revision as of 21:52, 6 June 2019
Dermatofibroma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Dermatofibroma pathophysiology On the Web |
American Roentgen Ray Society Images of Dermatofibroma pathophysiology |
Risk calculators and risk factors for Dermatofibroma pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]Faizan Sheraz, M.D. [3]
Overview
Dermatofibromas are composed of disordered collagen laid down by fibroblasts.
Pathophysiology
Dermatofibromas form as a reaction to previous injuries such as insect bites or thorn pricks. Dermatofibromas are composed of disordered collagen laid down by fibroblasts.
Immunohistochemical staining
Neoplasm | CD34 | Stromelysin-3[1] | Factor XIIIa |
---|---|---|---|
Dermatofibroma | + | + | + |
Dermatofibrosarcoma protuberans | + | - | - |
Video
{{#ev:youtube|tq4xFLIw1TA}}
Overview
The exact pathogenesis of [disease name] is not fully understood.
OR
It is thought that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].
OR
[Pathogen name] is usually transmitted via the [transmission route] route to the human host.
OR
Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell.
OR
[Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells].
OR
The progression to [disease name] usually involves the [molecular pathway].
OR
The pathophysiology of [disease/malignancy] depends on the histological subtype.
Pathophysiology
Physiology
The normal physiology of [name of process] can be understood as follows:
Pathogenesis
- The exact pathogenesis of [disease name] is not completely understood.
OR
- It is understood that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].
- [Pathogen name] is usually transmitted via the [transmission route] route to the human host.
- Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell.
- [Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells].
- The progression to [disease name] usually involves the [molecular pathway].
- The pathophysiology of [disease/malignancy] depends on the histological subtype.
Genetics
[Disease name] is transmitted in [mode of genetic transmission] pattern.
OR
Genes involved in the pathogenesis of [disease name] include:
- [Gene1]
- [Gene2]
- [Gene3]
OR
The development of [disease name] is the result of multiple genetic mutations such as:
- [Mutation 1]
- [Mutation 2]
- [Mutation 3]
Associated Conditions
Conditions associated with [disease name] include:
- [Condition 1]
- [Condition 2]
- [Condition 3]
Gross Pathology
On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
Microscopic Pathology
On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
- ↑ Kim HJ, Lee JY, Kim SH; et al. (2007). "Stromelysin-3 expression in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans: comparison with factor XIIIa and CD34". Br. J. Dermatol. 157 (2): 319–24. doi:10.1111/j.1365-2133.2007.08033.x. PMID 17596171. Unknown parameter
|month=
ignored (help)